Literature DB >> 32554753

Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Nidhi Dwivedi1,2, Shixin Tao1,2, Abeda Jamadar1,2, Sonali Sinha1,2, Christianna Howard1,2, Darren P Wallace1,2, Timothy A Fields1,3, Andrew Leask4, James P Calvet1,5, Reena Rao6,2.   

Abstract

BACKGROUND: Fibrosis is a major cause of loss of renal function in autosomal dominant polycystic kidney disease (ADPKD). In this study, we examined whether vasopressin type-2 receptor (V2R) activity in cystic epithelial cells can stimulate interstitial myofibroblasts and fibrosis in ADPKD kidneys.
METHODS: We treated Pkd1 gene knockout (Pkd1KO) mice with dDAVP, a V2R agonist, for 3 days and evaluated the effect on myofibroblast deposition of extracellular matrix (ECM). We also analyzed the effects of conditioned media from primary cultures of human ADPKD cystic epithelial cells on myofibroblast activation. Because secretion of the profibrotic connective tissue growth factor (CCN2) increased significantly in dDAVP-treated Pkd1KO mouse kidneys, we examined its role in V2R-dependent fibrosis in ADPKD as well as that of yes-associated protein (YAP).
RESULTS: V2R stimulation using dDAVP increased the renal interstitial myofibroblast population and ECM deposition. Similarly, conditioned media from human ADPKD cystic epithelial cells increased myofibroblast activation in vitro, suggesting a paracrine mechanism. Renal collecting duct-specific gene deletion of CCN2 significantly reduced cyst growth and myofibroblasts in Pkd1KO mouse kidneys. We found that YAP regulates CCN2, and YAP inhibition or gene deletion reduces renal fibrosis in Pkd1KO mouse kidneys. Importantly, YAP inactivation blocks the dDAVP-induced increase in myofibroblasts in Pkd1KO kidneys. Further in vitro studies showed that V2R regulates YAP by an ERK1/2-dependent mechanism in human ADPKD cystic epithelial cells.
CONCLUSIONS: Our results demonstrate a novel mechanism by which cystic epithelial cells stimulate myofibroblasts in the pericystic microenvironment, leading to fibrosis in ADPKD. The V2R-YAP-CCN2 cell signaling pathway may present a potential therapeutic target for fibrosis in ADPKD.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  polycystic kidney disease; renal fibrosis; vasopressin receptor

Mesh:

Substances:

Year:  2020        PMID: 32554753      PMCID: PMC7460894          DOI: 10.1681/ASN.2020020190

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  53 in total

Review 1.  The Hippo Pathway: A Master Regulatory Network Important in Development and Dysregulated in Disease.

Authors:  Cathie M Pfleger
Journal:  Curr Top Dev Biol       Date:  2017-01-19       Impact factor: 4.897

Review 2.  Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1.

Authors:  Thomas Weimbs
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-22

3.  A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.

Authors:  Vijayakumar R Kakade; Shixin Tao; Madhumitha Rajagopal; Xia Zhou; Xiaogang Li; Alan S L Yu; James P Calvet; Pankaj Pandey; Reena Rao
Journal:  J Mol Cell Biol       Date:  2016-05-04       Impact factor: 6.216

4.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

Authors:  Vincent H Gattone; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

5.  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Xiaofang Wang; Qi Qian; Stefan Somlo; Peter C Harris; Vincent H Gattone
Journal:  Nat Med       Date:  2004-02-29       Impact factor: 53.440

6.  Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia.

Authors:  P D Wilson; D Hreniuk; P A Gabow
Journal:  J Cell Physiol       Date:  1992-02       Impact factor: 6.384

7.  CTGF inhibits BMP-7 signaling in diabetic nephropathy.

Authors:  Tri Q Nguyen; Peggy Roestenberg; Frans A van Nieuwenhoven; Niels Bovenschen; Zeke Li; Leon Xu; Noelynn Oliver; Jan Aten; Jaap A Joles; Cecilia Vial; Enrique Brandan; Karen M Lyons; Roel Goldschmeding
Journal:  J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 10.121

8.  Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis.

Authors:  Hideki Yokoi; Masashi Mukoyama; Tetsuya Nagae; Kiyoshi Mori; Takayoshi Suganami; Kazutomo Sawai; Tetsuro Yoshioka; Masao Koshikawa; Takashi Nishida; Masaharu Takigawa; Akira Sugawara; Kazuwa Nakao
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

Review 9.  Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?

Authors:  Ingrid E Blom; Roel Goldschmeding; Andrew Leask
Journal:  Matrix Biol       Date:  2002-10       Impact factor: 11.583

10.  Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins.

Authors:  B V V G Reddy; Kenneth D Irvine
Journal:  Dev Cell       Date:  2013-03-11       Impact factor: 12.270

View more
  9 in total

1.  Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.

Authors:  Zhi-Yi Luo; Qi Tian; Niang-Mei Cheng; Wen-Han Liu; Ye Yang; Wei Chen; Xiang-Zhi Zhang; Xiao-Yuan Zheng; Ming-Sheng Chen; Qiu-Yu Zhuang; Bi-Xing Zhao; Cong-Sheng Liu; Xiao-Long Liu; Qin Li; Ying-Chao Wang
Journal:  Chin J Integr Med       Date:  2022-08-10       Impact factor: 2.626

2.  Renal plasticity revealed through reversal of polycystic kidney disease in mice.

Authors:  Ke Dong; Chao Zhang; Xin Tian; Daniel Coman; Fahmeed Hyder; Ming Ma; Stefan Somlo
Journal:  Nat Genet       Date:  2021-10-11       Impact factor: 41.307

3.  CCN1 interacts with integrins to regulate intestinal stem cell proliferation and differentiation.

Authors:  Jong Hoon Won; Jacob S Choi; Joon-Il Jun
Journal:  Nat Commun       Date:  2022-06-03       Impact factor: 17.694

4.  The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.

Authors:  Abeda Jamadar; Sreenath M Suma; Sijo Mathew; Timothy A Fields; Darren P Wallace; James P Calvet; Reena Rao
Journal:  Cell Death Dis       Date:  2021-10-14       Impact factor: 8.469

5.  Age-Related Downregulation of CCN2 Is Regulated by Cell Size in a YAP/TAZ-Dependent Manner in Human Dermal Fibroblasts: Impact on Dermal Aging.

Authors:  Zhaoping Qin; Tianyuan He; Chunfang Guo; Taihao Quan
Journal:  JID Innov       Date:  2022-02-22

6.  Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation.

Authors:  Abeda Jamadar; Nidhi Dwivedi; Sijo Mathew; James P Calvet; Sufi M Thomas; Reena Rao
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

7.  Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.

Authors:  Annarita Di Mise; Xiaofang Wang; Hong Ye; Lorenzo Pellegrini; Vicente E Torres; Giovanna Valenti
Journal:  FASEB J       Date:  2021-10       Impact factor: 5.834

Review 8.  Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.

Authors:  Xia Zhou; Vicente E Torres
Journal:  Front Mol Biosci       Date:  2022-09-02

9.  Polycystin-1 and hydrostatic pressure are implicated in glioblastoma pathogenesis in vitro.

Authors:  Ilianna Zoi; Antonios N Gargalionis; Kostas A Papavassiliou; Narjes Nasiri-Ansari; Christina Piperi; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  J Cell Mol Med       Date:  2022-02-01       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.